Publications & Presentations in the therapeutic area :

From In Vitro Efficacy to Long-term HbA1c Response for GLP-1R/GlucagonR Agonism using the 4GI-HbA1c Systems Model.

Bosch R., Petrone M., Arends R., Sijbrands E.J.G., Hoefman S.,  Snelder N. From In Vitro Efficacy to Long-term HbA1c Response for GLP-1R/GlucagonR Agonism using the 4GI-HbA1c Systems Model. PAGE 2024 [Link to publication]

Characterisation of cotadutide’s dual GLP-1/glucagon receptor agonistic effects on glycaemic control using an in vivo human glucose regulation quantitative systems pharmacology model.

Bosch R., Petrone M., Arends R., Vicini P., Sijbrands E.J. G., Hoefman S., Snelder N. Characterisation of cotadutide’s dual GLP-1/glucagon receptor agonistic effects on glycaemic control using an in vivo human glucose regulation quantitative systems pharmacology model. British Journal of Pharmacology, 2024 [Link to publication].

Quantification of the effect of GLP-1R agonists on body weight using in vitro efficacy information

Bosch R, Sijbrands E.J.G, Snelder N. Quantification of the effect of GLP-1R agonists on body weight using in vitro efficacy information: An extension of the Hall body composition model. CPT: Pharmacometrics & Systems Pharmacology, 2024 [Link to publication].

Linking 4GI Glucose Homeostasis and Hall Body Composition Models to study GLP-1R agonist effects on glucose and body weight.

Bosch R., Snelder N. Linking 4GI Glucose Homeostasis and Hall Body Composition Models to study GLP-1R agonist effects on glucose and body weight. PAGE 2023 [Link to publication]

Linking the 4GI glucose homeostasis and Hall body composition models to quantify weight loss effects of GLP-1R agonists, and body weight effects on insulin sensitivity.

Bosch R., Snelder N. Linking the 4GI glucose homeostasis and Hall body composition models to quantify weight loss effects of GLP-1R agonists, and body weight effects on insulin sensitivity. ACoP 2022. [Link to publication]

A novel integrated QSP model of in vivo human glucose regulation to support the development of a glucagon/GLP-1 dual agonist.

Bosch R., Petrone M., Arends R., Vicini P., Sijbrands E.J.G., Hoefman S., Snelder N. A novel integrated QSP model of in vivo human glucose regulation to support the development of a glucagon/GLP-1 dual agonist. CPT Pharmacometrics Syst Pharmacol, 2021. [Link to publication]

Successful prediction of continuous glucose dynamics and HbA1c response

Bosch R. Successful prediction of continuous glucose dynamics and HbA1c response to the GLP-1 and glucagon co-agonist cotadutide using the 4GI- HbA1c systems model The G lucose- G LP-1- G lucagon- G IP- I nsulin ( 4GI ) model. ASCPT 2021. (poster and lecture)

Integrate QSP model of in vivo human glucose regulation to support development of a glucagon/GLP-1 dual agonist

Bosch R., Petrone M.,Hoefman S., Arends R., Vicini P., Snelder N. Integrate QSP model of in vivo human glucose regulation to support development of a glucagon/GLP-1 dual agonist. WCDT 2019. [Link to publication]

Predicting the effect of GLP-1 agonists on glucose and HbA1c with a 4GI-HbA1c model

Bosch R., Petrone M., Hoefman S., Arends R., Vicini P., Snelder N. Predicting the effect of GLP-1 agonists on glucose and HbA1c with a 4GI-HbA1c model. ACOP, 2019. [Link to publication]

A novel integrated QSP model of in vivo human glucose regulation

Bosch R., Petrone M., Vicini P., Snelder N. A novel integrated QSP model of in vivo human glucose regulation to support development of a glucagon/GLP-1 dual agonist. PAGE, 2018. [Link to publication]

Expertise